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ABSTRACT The human ROSI gene, which possibly en-
codes a growth factor receptor, was found to be expressed in
human tumor cell lines. In a survey of 45 different human cell
lines, we found ROSI to be expressed in glioblastoma-derived
cell lines at high levels and not to be expressed at all, or
expressed at very low levels, in the remaining cell lines. The
ROSI gene was present in normal copy numbers in all cell lines
that expressed the gene. However, in one particular glio-
blastoma line, we detected a potentially activating mutation at
the ROSI locus.
We have reported the characterization of an activated ROSJ
gene which we previously called mcf3 (1). This gene was
identified using an assay for human protooncogenes based on
the tumorigenicity of mouse NIH 3T3 cells cotransfected
with human tumor DNA (2). mcf3 encodes a protein-tyrosine
kinase (ATP: protein-tyrosine O-phosphotransferase, EC
2.7.1.112) with a potential transmembrane domain. It arose
from the human ROSJ gene by a rearrangement introduced
during gene transfer, which deleted the putative extracellular
domain of ROSI, leaving potential transmembrane and in-
tracellular protein-tyrosine kinase domains intact (1). The
human ROSI is the closest homologue of the v-ros oncogene,
which is the transforming gene of the avian UR2 retrovirus
(3). Structurally mcf3 and v-ros are similar to the v-erbB,
v-fms, neu, and trk oncogenes (4-7). The cellular homologue
of two genes in this group, v-erbB and v-fms, are known to
encode the receptors for the epidermal growth factor and the
macrophage colony-stimulating factor, respectively (8, 9).
The cellular rosi gene may therefore encode a hormone or
growth factor receptor as well.
As a first step toward characterizing the normal ROSJ
gene, we have screened for its expression in a variety of
human cell lines established from normal and tumorigenic
cells. ROSI is expressed in a high proportion of human
glioblastoma cell lines and at very low levels, or not at all in
the remainder of human cell lines. We did not find detectable
levels of ROSI in either human brain or in a cell line
established from a normal human glial cell. In most glio-
blastoma cell lines, the ROSI-encoded transcript was found
to be 8.3 kilobases (kb) in size. Upon analysis of the ROSI
locus by Southern blotting, an aberrant configuration due to
a rearrangement in sequences encoding the putative extra-
cellular domain, was seen in one particular glioblastoma cell
line.
MATERIALS AND METHODS
ROSI Expression Studies. Total RNA from various human
tumor cell lines and tissues was prepared by the guanidinium/
cesium chloride method (10). Human placenta was obtained
from elective cesarean sections and superficially normal
brain tissue (temporal lobe) from a patient undergoing sur-
gery for epilepsy. The quantity of RNA was determined by
measurements of the optical density, and the quality and
quantity of the RNA preparations were verified on glyoxal
gels (11). Twenty micrograms of total RNA was hybridized
overnight at 520C to =1 fmol of 32P-labeled RNA transcript
produced by Sp6 RNA polymerase (specific activity, 8 X 1
dpm/pmol) as described (12). The hybridization mixture was
diluted 10-fold with buffer containing 50 mM sodium acetate
(pH 4.5)/2 mM EDTA/100 mM NaCl to a final volume of 300
pl and treated with 10 units ofRNase T2 for 1 hr at 30'C. The
nucleic acids were precipitated with ethanol and analyzed on
a 5% acrylamide gel containing Tris/borate/EDTA buffer
and 8 M urea, which was autoradiographed. A complete
description of the cell lines used for the expression studies,
with the exception of cell lines CJ, DI, El, SN, and HF, can
be obtained from Jim Loveless, the Human Tumor Cell Line
Bank, Human Tumor Cell Laboratory, Memorial Sloan-Ket-
tering Cancer Institute. Cell lines CJ, DI, El, and SN are
human glioblastoma lines and primary glial cells, respective-
ly, established by J. Shapiro at Memorial Sloan-Kettering
Cancer Institute. HF cells are primary human foreskin
fibroblasts obtained from J. Feramisco, Cold Spring Harbor
Laboratory.
Southern and RNA Blot Analysis. Southern blot analysis
was done as described (13). RNA for blotting was isolated by
the guanidinium/cesium chloride method and was subse-
quently purified on oligo(dT) columns (11). RNA blotting was
done essentially as described (14). For hybridization, the
same ROS1 probe synthesized by Sp6 RNA polymerase and
described was used. The RNA blot was hybridized for 36 hr
at 62°C in 50%6 formamide/5 x standard saline citrate (SSC)
(lx SSC is 0.15 M sodium chloride/0.015 M sodium citrate)/
10 mM EDTA/10 ,ug of carrier DNA per ml/5 x Denhardt's
solution (lx Denhardt's solution is 0.02% polyvinylpyr-
rolidone/0.02% Ficoll/0.02% bovine serum albumin), and
washed in 0.1 x SSC/0.1% NaDodSO4 once for 2 min at room
temperature and four times for 30 min at 64°C.
RESULTS
We previously reported the isolation of a cDNA correspond-
ing to the transcript of an activated ROS1 gene, mcf3 (1). A
portion of this cDNA encoding amino acids 140-295 was
subcloned into pSp65, a vector containing a Sp6 RNA
polymerase promoter (12). A 32P-labeled Sp6 RNA polymer-
ase transcript of the overall length of 730 nucleotides (nt),
containing 460 nt ofmcJ3 sequence complementary to ROSl-
encoded mRNA and 270 nt of sequence derived from the
vector was synthesized and gel purified. This transcript was
hybridized in solution to total RNA prepared from a variety
of human tumor cell lines and was then digested with RNase
(12). The RNA hybrids protected from nuclease digestion
were subsequently analyzed on denaturing acrylamide gels.
Fig. 1 shows, as an example, the analysis of RNA from six
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mRNA per cell. mcf3 transcripts were still detected on 0.025
,4g of the total RNA from MCF-7-3-7 cells after autoradi-
ograms were exposed for 1 week, which indicated that the
detection limit of this assay was 0.25 pg of mcf3 mRNA. In
all experiments, RNA from MCF-7-3-7 was used in parallel to
estimate the levels ofROSI transcripts in tested RNAs. Table
1 summarizes the result of these experiments and includes
name and tissue of origin of tested cell lines together with the
approximate number ofROSI transcripts found in these cells.
Table 1. ROSI transcripts in tested human cell lines and tissues
ROSI
transcripts
Human cell line per cell,*
or tissue Origin =no.
.
-309
FIG. 1. Expression of ROSI in glioblastoma cells. Total RNA
from human glioblastoma and mouse MCF-7-3-7 cells was hybridized
to the 32P-labeled RNA transcript synthesized by Sp6 RNA polym-
erase as described. After digestion of the single-stranded RNA with
RNase T2, the nucleic acids were analyzed on an acrylamide gel
under denaturing conditions. The figure was photographed from an
autoradiogram exposed for 36 hr. Numbers at right, size of DNA
marker fragments in nt. Bar at left (P), fragment protected from
RNase T2 digestion by mcf3 orROSJ-encoded RNA. Lanes: 1, 0.033
Mug of RNA from MCF-7-3-7 and 20 Mig of yeast tRNA; 2, 0.1 Mg of
RNA from MCF-7-3-7 and 20 Mig of yeast tRNA; 3, 0.33 ,g of RNA
from MCF-7-3-7 and 20 Mug of yeast tRNA; 4, 1 ,ug of RNA from
MCF-7-3-7 and 20 ,ug of yeast tRNA; 5, 10 Mg of RNA from human
U-343 MG cells and 10 Mug of yeast tRNA; 6, 20 Mig of RNA from
human SW-1088 cells; 7, 20 Mg ofRNA from human U-118 MG cells;
8, 20 Mg ofRNA from human U-251 MG cells; 9, 20 Mg ofRNA from
human U-105 MG cells; 10, 20 M&g of RNA from human U-138 MG
cells; M, pBR322 DNA cut with Msp I; and I, labeled-RNA transcript
before RNase T2 treatment.
different glioblastoma cell lines by this technique. The
original transcript of 760-nt length used for hybridization is
shown in lane I. RNA from MCF-7-3-7, a mouse NIH 3T3 cell
line transformed by mcf3 (1), protects a fragment of 460 nt
from digestion by RNase because only 460 nt of the labeled
probe are complementary to mcf3-encoded RNA (Fig. 1, lane
1-4). RNA from glioblastoma cell lines protected a fragment
identical in length (Fig. 1, lanes 5-10). Thus ROSJ transcripts
are presented in the tested glioblastoma lines. As can be seen
in Fig. 1, the protected probe resolved into a doublet on
denaturing acrylamide gels. This was reproducibly observed
with RNAs from all cell lines that protected this probe. The
appearance of this doublet might either reflect a heterogene-
ity in the mcf3- and ROSI-encoded mRNA or might be an
artifact due to strong secondary structures within the pro-
tected fragment.
The intensity of the band on the autoradiogram corre-
sponding to the protected fragment can be used to quantify
the amount of ROSJ transcripts in the tested RNA. For
standardization, we used RNA from cell line MCF-7-3-7 and
determined the counts present in the protected fragment after
analysis by scintillation counting. Five micrograms of total
RNA from MCF-7-3-7 cells protected 5000 dpm of the labeled
probe (specific activity, 8.107 dpm/pmol) or 0.06 fmol; 0.06
fmol corresponds to 50 pg of the 2.5-kb mcf3-encoded
mRNA. Assuming that hybridization went essentially to
completion, 50 pg of mcf3 mRNA was present in 5 ,ug of the
total RNA. Assuming that 2% of total RNA is mRNA, this
amount of mcf3 mRNA represents 0.05% of the mRNA; and
assuming 400,000 mRNA molecules per cell, this amount
would correspond to =200 molecules of mcf3-encoded
U-343 MG
U-118 MG
El
U-105 MG
U-178 MG
U-251 MG
U-138 MG
SW-1088
DI
CJ
A-172
A-382
SN
Wiltu-1
SK-NEP-l
Caki-l
RD-2
575A
TCCSUP
VM-CUB-2
486P
MCF7
734B
SK-Br-3
SK-N-MC
SK-N-SH
SK-HEP-l
LS-174T
HT-29
SW-480
8387
SK-MEL-3
RPMI-4445
C4II
RPMI-2650
Fadu
RPMI-8402
SK-L3
U-698 M
NB-58B
Calu-3
SK-MES-1
SW-982
HF
A431
Brain, temporal lobe
Placenta
ND, not detected.
Glioblastoma multiforme
Glioblastoma multiforme
Glioblastoma multiforme
Astocytoma, grade III
Astocytoma, grade II
Astocytoma, grade I
Glioblastoma, not graded
Glioblastoma, not graded
Glioblastoma multiforme
Glioblastoma, astocytoma,
medium grade
Glioblastoma, not graded
Glioblastoma, not graded
Normal glial cells
Kidney, Wilm tumor
Kidney, Wilm tumor
Kidney, carcinoma
Rhabdomyosarcoma
Bladder, carcinoma
Bladder, carcinoma
Bladder, carcinoma
Bladder, carcinoma
Breast, carcinoma
Breast, adenocarcinoma
Breast, carcinoma
Neuroblastoma
Neuroblastoma
Liver, adenocarcinoma
Colon, adenocarcinoma
Colon, adenocarcinoma
Colon, adenocarcinoma
Bone, sarcoma
Melanoma
Melanoma
Cervix, carcinoma
Nasal, squamous cell
carcinoma
Pharynx, squamous cell
carcinoma
Leukemia, lymphoplastic
Leukemia, myelomonocytic
Lymphoma
Normal lymphocyte
Lung, adenocarcinoma
Lung, squamous cell
carcinoma
Fibrosarcoma
Normal fibroblasts
Epidermoid carcinoma
60
10
10
3
<1
<1
10
10
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
<1
<1
ND
ND
<1
ND
ND
ND
ND
ND
ND
ND
<1
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
*For calculations, it was assumed that there were 400,000 mRNA
molecules per cell and that 2% of the total RNA represents mRNA.
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In addition to glioblastoma cell lines, four other cell lines
(TCCSUP, VM-CUB-2, 734B, and 8387) expressed detect-
able levels ofROSI transcripts, albeit at low levels, estimated
to correspond to <1 transcript per cell. We did not find
detectable levels ofROSI expression in the remaining 28 cell
lines, including SN, a cell line established from normal
human glial cells; nor did we detect ROSI expression in the
two analyzed tissues, placenta and brain.
We have previously shown that the human ROSJ gene can
be activated by either deletion of the putative extracellular
domain and/or by amplification (1). It was therefore of
interest to determine whether the ROSI genes in the human
tumor cell lines that express ROSI are present in normal copy
number and in normal configuration. In all Southern blots the
fragments detected by the ROSI probe were of similar
intensities in placental and tumor DNAs, indicating ROSI
genes in the tumor DNAs to be present in normal copy
number. To study potential rearrangements, we confined our
analysis of the genomic ROSI DNA to the part encoding the
junction of the putative extracellular and transmembrane
domains. For Southern blotting, we used a genomic EcoRI
fragment 5.2 kb in length containing three exons that encode
70 amino acids of the putative extracellular domain, the
potential transmembrane domain, and 42 amino acids of the
putative intracellular domain (1, 15) (see diagram at bottom
of Fig. 2). In placental DNA, this probe hybridized mainly to
a 9.5-kb BamHI fragment (Fig. 2, lane 1). The position of this
fragment within the ROSI locus is depicted in the diagram at
the bottom of Fig. 2. A fragment identical in size was seen in
the DNAs from all tested cell lines with the exception of cell
line U-118 MG, where a 20-kb fragment was detected (Fig. 2);
U-118 MG is a cell line derived from a glioblastoma and
contains 10 ROSI transcripts per cell. To exclude that
altered mobility of this fragment was due to a restriction
3 4 567
Proc. Nati. Acad. Sci. USA 84 (1987)
endonuclease-fragment length polymorphism, the same
probe was used for Southern blot analysis of DNA digested
with a different restriction enzyme, HindIII. In placental
DNA and DNA from six other cell lines, two fragments, 1.5
kb and 5.5 kb, were recognized by this probe (Fig. 3). In DNA
from U-118 MG cells, the common 1.5-kb fragment and an
unusual 2.25-kb fragment were seen (Fig. 3, lane 6). This
demonstrates that the ROSJ gene in cell line U-118 MG DNA
has an unusual conformation and is probably rearranged.
Further support of this conclusion is the fact that in cell line
U-118 MG DNA we detected only the aberrant DNA frag-
ments, demonstrating that U-118 MG cells are homozygous
for the altered ROSI gene. Additional Southern blotting data
with cDNA probes indicate that at least some of the se-
quences encoding the putative extracellular domain are
missing from cell line U-118 MG (data not shown).
Southern blot analysis allowed us to map the point of
divergence between the placental and U-118 MG ROSI
alleles within the 5.2-kb EcoRI fragment. Prolonged exposure
of the Southern blots shown in Fig. 2 revealed a second
BamHI fragment that was 10 kb in length and common to all
cell lines except cell line U-118 MG (data not shown). The
position of this BamHI fragment within the ROS) locus is
shown in the diagram at the bottom of Fig. 2. In U-118 MG
DNA, BamHI fragments of 9.5 kb and 10 kb are both altered;
the 1.5-kb HindIII fragment is intact, whereas the 5.5-kb
HindIII fragment is altered. The altered HindIII fragment
spans the BamHI site within the 5.2-kb EcoRI fragment.
Therefore, this BamHI site is apparently lost. The point of
divergence is thus located within the same fragment we have
previously seen rearranged in mcf3.
To determine the size of the ROSI transcripts in the
glioblastoma cell lines, RNA blotting of different lines was
done. RNA from cell line SK-MES-1 served as a negative
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FIG. 2. Southern blot analysis of the ROSI locus in
different cell lines expressing ROSI. Genomic DNA
(-10 ,g) and DNA (0.1 ng) from a ROSI cosmid clone
(3P7) derived from human placental DNA were digest-
ed with BamHI and analyzed by Southern hybridiza-
tion. As a probe, the 5.2-kb EcoRI fragment, indicated
by a bold line in the lower diagram was used; positions
ofthe three exons within this fragment are indicated. In
addition, the restriction map of the ROS) locus around
this fragment is shown. The cloned piece of the ROSI
locus is depicted by a solid line, and the mapped part
is depicted by a broken line. The EcoRI sites in the
cloned region are shown by vertical lines. BamHI sites
and relevant HindIII sites are indicated by arrows and
the letters B and H, respectively. Numbers between
arrows indicate the size of the HindIII and BamHI
fragments in kb pairs. The bracket between exon 1 and
exon 2 shows the location of the rearrangement in
mcf3. Lanes: 1, placental DNA; 2, DNA from MCF7
cells; 3, DNA from VM-CUB-2 cells; 4, DNA from
TCCSUP cells; 5, DNA from 734B cells; 6, DNA from
SW-1088 cells; 7, DNA from 8387 cells; 8, DNA from
U-105 MG cells; 9, DNA from U-118 MG cells; 10,
DNA from U-138 MG cells; 11, DNA from U-343 MG
cells; and 12, 3P7 DNA. Intensity difference of the
hybridizing fragments between the lanes reflects dif-
fering amounts ofDNA applied, asjudged by ethidium
bromide staining of the gel before transfer. Numbers at
left and right of the Southern blot indicate DNA marker
size. The second hybridizing fragment in lane 12, which
is -19 kb long, corresponds to a fragment containing
t cosmid sequences that hybridize to the plasmid se-
B quences of the probe.
B
B
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i2 3 4 5 6 7 8 9 transcripts of 8.3-kb (Fig. 4, lanes 2, 4, and 5). In the fourth
glioblastoma cell line, U-118 MG, which contains an aberrant
configuration of the ROSI gene, a smaller 4-kb ROSI
transcript, is seen (Fig. 4, lane 3).
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FIG. 3. Aberrant configuration of the ROSI locus in U-118 MG
DNA. Genomic DNA (-10 Ag) and DNA (0.1 ng) of a cosmid clone
(3P7) were cut with HindIll and analyzed by Southern hybridization.
As a probe, a plasmid containing the 5.2-kb EcoRI fragment,
indicated by a bold line in the diagram of Fig. 2 was used. Numbers
at left, sizes of hybridizing fragments; numbers at right, sizes ofDNA
marker fragments. Lanes: 1, DNA from placenta; 2, DNA from
MCF-7; 3, DNA from SW-1088; 4, DNA from SW-1783; 5, DNA
from U-105 MG; 6, DNA from U-118 MG; 7, DNA from U-138 MG;
8, DNA from U-343 MG; 9, DNA from 3P7. The second hybridizing
fragment in lane 9, "17 kb, corresponds to a fragment containing
cosmid sequences that hybridize to the plasmid sequences of the
probe.
control (Fig. 4, lane 1). In three glioblastoma lines, SW-1088,
U-343 MG, and U-105 MG, the structure of the ROS) gene
appeared normal by Southern blot analysis. In RNA of these
three cell lines, we detected comigrating ROSJ-encoded
2 3 4 5
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FIG. 4. RNA analysis from glioblastoma cell lines. Different
RNA preparations were fractionated by gel electrophoresis, trans-
ferred to nitrocellulose, and hybridized to a ROSJ-derived cDNA
probe. Lanes: 1, 10 ,ug of poly(A)+ RNA from SK-MES-1; 2, 10 j.g
of poly(A)+ from U-105 MG;3, 10 ,ug of poly(A)+ RNA from U-118
MG; 4, 10 ,ug of poly(A)+ RNA from SW-1088; and 5, 20 ,ug of total
RNA from U-343 MG. Lanes 1-3 and lanes 4 and 5 originate from two
different RNA blots; lanes 4 and 5 were photographed from autoradi-
ograms exposed for different times. Transcript sizes were deter-
mined by comparison with the mobility of 35S-labeled RNA tran-
scripts produced by Sp6 RNA polymerase of 7.5 kb, 5.3 kb, 4.6 kb,
4.2 kb, and 3.2 kb.
DISCUSSION
We have found expression of the ROSJ gene in human tumor
cell lines. In cell lines established from glioblastomas we
frequently detected ROSJ transcripts ranging from below one
transcript to 60 transcripts per cell. By contrast, we found
only low levels ofROSJ transcripts (below one transcript per
cell) in 4 out of 32 other cell lines. The weakly positive cell
lines originated from two bladder carcinomas, one breast
carcinoma, and one osteosarcoma. In the remaining cell
lines, levels of ROS) transcripts were below our detection
limit. In a similar survey of human tumor cell lines, other
workers failed to detect expression ofROSJ in any lines (16),
although that survey may not have included glioblastoma
cells. Moreover, we see no expression of a ROSJ gene in
normal brain tissue. Thus the high level of ROSJ expression
in glioblastomas seems specific.
A transcript in low abundance that hybridizes to a v-ros
probe has been previously reported in RNA from kidneys of
7- to 14-day-old chicken. Due to RNA degradation, the size
of this transcript could not be determined (17). Discovery of
cells that express a ROSJ gene in abundance has allowed us
to determine the size of the ROSJ transcript. As determined
by RNA blotting, the size of the ROSJ-encoded mRNA in
three glioblastoma lines was found to be 8.3 kb and the
mRNA has, thus, the potential to encode a large protein.
Preliminary immunoprecipitation studies indicate this is the
case (S.S., unpublished work). The ROSI transcript in one
other glioblastoma cell line, U-118 MG, was found to be 4 kb.
As determined by Southern blotting, the ROSI locus ofU-118
MG does have an aberrant configuration and therefore was
expected to produce an altered ROSI transcript.
Southern blot analysis indicated that ROSI was present in
normal copy number in all tumor cell lines expressing the
gene. However, an aberrant ROSI locus was found in one of
the glioblastoma cell lines, U-118 MG. The point of diver-
gence between the normal and U-118 MG ROSI genes was
located to that portion of ROSI that encodes the junction
between the putative extracellular and transmembrane do-
mains. Our analysis indicated that sequences downstream
from the point ofdivergence were intact. This region encodes
the putative intracellular domain ofROSI. However, at least
part of ROSI encoding putative extracellular sequences are
missing in U-118 MG DNA, and preliminary data indicate
that U-118 MG cells do produce high levels of an altered
ROSI-encoded protein (S.S., unpublished work). Interest-
ingly, the point of rearrangement in U-118 MG DNA is very
close to the point of rearrangement that created the mcf3
gene. In mcf3, this leads to deletion of all but eight amino
acids of the putative extracellular domain of ROSJ (1). Loss
of the putative extracellular domain is also seen in v-ros (3).
Thus deletions of this domain may be an important event in
the activation of the oncogenic potential of the ROSI gene.
Presently, we cannot be sure of the contribution of ROSI
expression to the pathogenesis of glioblastomas, although
several observations suggest a possible role. First, expres-
sion of ROSI, a potential oncogene, appears specific to
glioblastomas. We do not see expression ofROSI in normal
brain RNA. Second, one glioblastoma cell contains in all
likelihood an "activating" deletion within the ROSI gene and
is homozygous for this mutation. For these reasons we
propose that ROSI expression contributes to the develop-
ment of glial tumors. ROSI is not the only potential oncogene
expressed in this cell type. The epidermal growth factor
receptor (EGFR) gene is frequently amplified and expressed
Medical Sciences: Birchmeier et al.
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at high levels in primary human glioblastomas, and an
aberrant configuration of the EGFR gene has been seen in
one particular tumor of glial origin (18).
Sequence data strongly suggest that ROSI is a membrane-
spanning protein and therefore specifies an extracellular
antigen. Thus, antibodies recognizing the putative extracel-
lular domain might be clinically useful in diagnosis or imag-
ing. Moreover, because ROS) does not seem to be ubiqui-
tously expressed, such antibodies might also find application
in the specific treatment of tumors of glial origin.
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